Clinical Trials Sponsored by Shanghai Kechow Pharma, Inc.

Total 21 results

Kechow Pharma, Inc.

Completed

Study of HL-085 in Patients With Advanced Solid Tumor Tumors

Solid Tumor, Adult

United States
Shanghai Kechow Pharma, Inc.

Recruiting

A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation

Solid Tumor

China
Shanghai Kechow Pharma, Inc.

Terminated

Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC

Nsclc

China
Shanghai Kechow Pharma, Inc.

Not yet recruiting

Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study

Non-small-cell Lung Cancer
Shanghai Kechow Pharma, Inc.

Recruiting

HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation

Melanoma

China
Shanghai Kechow Pharma, Inc.

Completed

Study of HL-085 in NRAS Mutant Advanced Melanoma

Melanoma

China
Shanghai Kechow Pharma, Inc.

Completed

HL-085 in NRAS-mutated Advanced Melanoma

Melanoma

China
Shanghai Kechow Pharma, Inc.

Not yet recruiting

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Colorectal Cancer Metastatic
Shanghai Kechow Pharma, Inc.

Not yet recruiting

Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

Melanoma

China
Shanghai Kechow Pharma, Inc.

Recruiting

HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Neurofibromatosis 1 | Plexiform Neurofibromas

China
Shanghai Kechow Pharma, Inc.

Recruiting

Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC) (mCRC)

CRC

China
Shanghai Kechow Pharma, Inc.

Terminated

Phase I Study of HL-085 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States
Beta Pharma Shanghai

Completed

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

NSCLC

China
Beta Pharma Shanghai

Completed

BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Beta Pharma Shanghai

Active, not recruiting

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

NSCLC

China
Shanghai Pharma Biotherapeutics USA Inc.

Recruiting

Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

Liposarcoma, Dedifferentiated

United States
Shanghai Pharma Biotherapeutics USA Inc.

Recruiting

Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis

Ulcerative Colitis

United States
Shanghai YingLi Pharmaceutical Co. Ltd.
Yingli Pharma US, Inc

Recruiting

YL-13027 in Patients With Advanced Solid Tumors

Solid Tumor

United States
Shanghai YingLi Pharmaceutical Co. Ltd.
Yingli Pharma US, Inc

Recruiting

A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation

Advanced Solid Tumor

United States
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
Oyster Point Pharma, Inc.

Completed

Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease

Dry Eye Disease

China
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
Oyster Point Pharma, Inc.

Completed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of OC-01 in Adult Chinese With Dry Eye Disease

Dry Eye Disease

China

3

Subscribe